Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Currently, the sequelae and short-term medical and psychological impact of the sars-cov-2 infection ("CoVID-19") remain poorly described. The clinical and functional sequelae that may persist after acute sars-cov-2 ("CoVID-19") infection are essential to explore, in order to ensure the best possible follow-up of patients after discharge from hospital.
Description: assessed by 0-10 Borg scale
Measure: Assessment of dyspnea Time: 3 to 6 months after Sars coV 2 infectionDescription: assessed by lung CT scan
Measure: Description of pulmonary lesions as assessed by lung CT scan Time: 3 to 6 months after Sars coV 2 infectionDescription: assessed by lung CT scan
Measure: Development of pulmonary fibrosis as assessed by lung CT scan Time: 3 to 6 months after Sars coV 2 infectionDescription: assessed by incidence of cardiovascular events, venous thromboembolism, and transthoracic echocardiogram
Measure: Incidence or worsening of cardiovascular diseases Time: 3 to 6 months after Sars coV 2 infectionDescription: renal function and urinary parameters
Measure: Incidence or worsening of renal disease Time: 3 to 6 months after Sars coV 2 infectionDescription: hepatic blood parameters
Measure: Incidence or worsening of liver disease Time: 3 to 6 months after Sars coV 2 infectionDescription: assessed by validated scale: Generalized Anxiety Disorder-7 (GAD7)
Measure: Incidence or worsening of psychological pathology : anxiety Time: 3 to 6 months after Sars coV 2 infectionDescription: assessed by validated scales: Patient Health Questionnaire-9 (PHQ9)
Measure: Incidence or worsening of psychological pathology: depression Time: 3 to 6 months after Sars coV 2 infectionDescription: assessed by validated scale : Post-traumatic Checklist for DSM-5 (PCL-5)
Measure: Incidence or worsening of psychological pathology: post-traumatic stress Time: 3 to 6 months after Sars coV 2 infectionDescription: assessed by validated scale : insomnia severity index (ISI)
Measure: Incidence or worsening of psychological pathology: insomnia Time: 3 to 6 months after Sars coV 2 infectionDescription: assessed by validated scale (EQ-5D-L questionnaire)
Measure: Assessment of the health-related quality of life Time: 3 to 6 months after Sars coV 2 infectionDescription: assessed by the fatigue severity sale
Measure: Assessment of the fatigue Time: 3 to 6 months after Sars coV 2 infectionDescription: assessed by the Evaluation of Deprivation and Inequalities in Health Examination (EPICES) scale
Measure: Assessment of the socioeconomic deprivation Time: 3 to 6 months after Sars coV 2 infectionDescription: assessed by blood glucose level, HbA1C, lipid blood tests, TSH, T3, T4, antithyroperoxydase antibodies, cortisol, ACTH, renin, aldosteron, albumin level, vitamin D level, iron status, weight changes
Measure: development or worsening of metabolic disorders: diabetes, thyroid diseases, dyslipidemia, adrenal disorders, malnutrition Time: 3 to 6 months after Sars coV 2 infectionDescription: assessed by lupus anticoagulant, anti-cardiolipin, anti-β2-glycoprotein
Measure: Development of auto-immune disorders Time: 3 to 6 months after Sars coV 2 infectionDescription: Presence and levels of anti-SARS-CoV-2 antibodies of IgG, IgA and IgM isotypes
Measure: Assessment of the evolution of the humoral anti-SARS-CoV-2 immunization profile Time: 3 to 6 months after Sars coV 2 infectionDescription: assessed by the International Physical Activity Questionnaire (IPAQ)
Measure: Patients' self-reported level of physical activity Time: 3 to 6 months after Sars coV 2 infectionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports